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Background:  Indonesia  faces  an  HIV  epidemic  that  is in  rapid transition.  Injecting  drug  users  (IDUs)  are
among  the  most  heavily  affected  risk  populations,  with  estimated  prevalence  of  HIV  reaching  50%  or  more
in  most  parts  of  the  country.  Although  Indonesia  started  opening  methadone  clinics  in 2003,  coverage
remains  low.
Methods:  We  used  the  Asian  Epidemic  Model  and  Resource  Needs  Model  to evaluate  the  long-term
population-level  preventive  impact  of  expanding  Methadone  Maintenance  Therapy  (MMT)  in  West  Java
(43  million  people).  We  compared  intervention  costs  and  the  number  of  incident  HIV  cases  in  the  inter-
vention  scenario  with  current  practice  to  establish  the cost  per  infection  averted  by  expanding  MMT.
An  extensive  sensitivity  analysis  was  performed  on  costs  and  epidemiological  input,  as  well  as  on  the
cost-effectiveness  calculation  itself.
Results: Our  analysis  shows  that  expanding  MMT  from  5% coverage  now  to  40%  coverage  in 2019  would
avert  approximately  2400  HIV  infections,  at a  cost  of  approximately  US$7000  per HIV  infection  averted.
Sensitivity  analyses  demonstrate  that  the use  of  alternative  assumptions  does  not  change  the  study
conclusions.
Conclusion:  Our  analyses  suggest  that  expanding  MMT  is  cost-effective,  and  support  government  policies
to  make  MMT  widely  available  as  an  integrated  component  of  HIV/AIDS  control  in  West  Java.
© 2012 Elsevier B.V. 
Introduction
Apart from sub-Saharan Africa, HIV epidemics are mainly con-
centrated among most-at-risk populations (WHO/UNAIDS, 2007).
Injecting drug users (IDUs) constitute an important risk group, esti-
mated at 15.9 million individuals globally, of whom 3 million are
HIV-infected. The size of the IDU population and the prevalence of
HIV in this population have increased in the past decade (Mathers
et al., 2008).
Indonesia has signiﬁcantly contributed to this increase. HIV
increased considerably in Indonesia from the mid-1990s onwards,
paralleling the rapid rise of opioid use. Indonesia currently faces an
∗ Corresponding author at: Radboud University Nijmegen Medical Centre, Depart-
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HIV epidemic in rapid transition: there has been a rapid rise in HIV
incidence among IDUs, followed by a heterosexual epidemic among
female sex workers (FSWs) and their clients, and subsequently
among men having sex with men  (MSM)  (Des Jarlais et al., 2012).
By 2007, approximately 50% of IDUs were infected (in Jakarta 55%,
Bandung 43%, Medan 56%, and Surabaya 56%) (MOH-Indonesia,
2007; UNAIDS/WHO, 2008), contributing to at least 40% of new
HIV infections. In 2015, it is expected that one million Indonesians
will be HIV-infected and 350,000 will have died because of AIDS
(NAC-Indonesia, 2008a,b).
Acknowledging  the important role of injecting drug use,
Indonesia adopted legislation in 2004 supporting harm reduc-
tion activities, including methadone maintenance therapy (MMT)
(Mesquita et al., 2007). Despite ambitious policy targets, MMT
coverage remains low, mainly because of its high costs, lack of
capacity to expand continuously, and the recent tightening of drug
laws (Chatterjee & Sharma, 2010; Sharma, Oppenheimer, Saidel,
Loo, & Garg, 2009). In 2003, a pilot study in Jakarta showed that
MMT signiﬁcantly reduces injection frequency and IDU-associated
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HIV risk behaviours (Lawrinson et al., 2008). However, many IDUs
continue to inject, and therefore remain at risk of transmitting
HIV or becoming infected themselves. This situation raises ques-
tions regarding the population-level preventive impact of MMT.
Do intermediate behavioural outcomes also translate into ﬁnal out-
comes as infections averted at the populational level? In this sense,
what are the long-term effects of MMT?  van den Berg, Smit, Van
Brussel, Coutinho, and Prins (2007) showed that full participation
in harm reduction (both MMT  and NSP) programs is associated with
a reduced HIV transmission in the Netherlands (van den Berg et al.,
2007), but it is questionable whether these results are also applica-
ble to the Indonesian context. Moreover, the resource requirements
for harm reduction in Asia in 2009 were estimated at $500 mil-
lion and MMT  accounted for a signiﬁcant share of these resources
(Bergenstrom et al., 2010). Therefore, careful assessment of both
the costs and effects of prevention measures is warranted to further
inform decisions about whether to expand MMT  to higher coverage
levels.
The research question in this paper is: from the societal perspec-
tive, what are the costs and effects of expanding MMT  compared
with current practice? This paper is the ﬁrst to address the
cost-effectiveness of MMT  as an HIV prevention measure in a low-
income setting. We  chose a modeling design to study the effects of
MMT  on long-term HIV transmission at the populational level. We
used the Asian Epidemic Model (AEM), a well validated and widely
used HIV transmission model. Most importantly, the AEM com-
prises all relevant risk groups and allows behaviour to change over
time (Brown & Peerapatanapokin, 2004; Saidel et al., 2003). We
describe HIV transmission in the West Java province, explore the
role of IDUs, and relate this role to cost-effectiveness analysis. West
Java is Indonesia’s most populous province (43 million people) and
has one of the highest populations of HIV-infected individuals in
Indonesia.
Methods
HIV transmission model
We  used the AEM (Brown & Peerapatanapokin, 2004; Saidel
et al., 2003) to simulate the epidemiology of HIV among the vari-
ous risk groups in West Java. Our starting point of analysis was the
AEM model as ﬁtted for West Java by AIDsina and the East-West
Centre, two local specialised institutes on HIV/AIDS epidemiology
and modeling that developed the model and also calculated the
national HIV/AIDS projections (NAC-Indonesia, 2008b). The param-
eters were varied to ﬁnd the model ﬁt as shown in Table 1, and risk
behaviour was assumed constant after 2007.
The current practice scenario assumed a coverage of MMT  of
1.5% in 2008 (Sharma et al., 2009), extrapolated to 5% in 2010 and
remaining constant thereafter. The intervention scenario assumed
a similar MMT  coverage till the end of 2009 followed by a lin-
ear increase to 40% in 2019, following UNAIDS recommendations
(Verster, Clark, Ball, & Donoghoe, 2007). In both scenarios, the
impact of MMT  was modeled through changes in the prevalence
and frequency of unsafe injecting drug use (the frequency of injec-
tions and percentages of needle-sharing) and condom use among
IDUs, derived from the intervention impact matrix of the Resource
Needs Model (RNM) (Bollinger, Stover, & Sangrujee, 2007) (Table 2).
To estimate the impact of our intervention scenario, we ran
current practice and intervention scenarios and compared the
resulting annual numbers of new infections. We  performed exten-
sive one-way sensitivity analysis on all IDU-related parameters.
Additionally, to cope with uncertainty in surveillance studies,
we changed (±25%) functionally related clusters of both sexual
and injecting behaviour parameters and single key parameters
(based  on our own data search). These scenarios were again ﬁtted
with observed HIV prevalences and used for alternative cost-
effectiveness calculations.
Cost  analysis
We  also employed the RNM to estimate the cost of our interven-
tion, and linked unit cost estimates to the number of people utilising
MMT.  Unit costs of MMT,  from the societal perspective, were taken
from Afriandi et al. (2010), which was  also conducted in West Java.
To summarise the ﬁndings of Afriandi et al. (2010), this study pro-
vides full details about the costs of MMT.  MMT  service delivery costs
were estimated using a micro-costing approach. Data regarding
service utilisation (such as attendance, methadone dosage, labo-
ratory and other investigations, and referrals to medical services)
were retrieved from the clinic’s records from November 2006 to
October 2007. Capital costs and other recurrent costs (such as per-
sonnel, training, and other resources used) were calculated on the
basis of ﬁnancial administrative data. Patient costs were estimated
on the basis of a survey among 48 methadone clients. This sur-
vey included information about travel costs and travelling time,
monthly income, and the average number of daily working hours.
This information was combined with the average total time spent
per client in the clinic. All capital costs (including training and
workshops), personnel costs, methadone supply, and other sup-
plies were included in the health care system perspective. The
societal perspective also included patient costs.
The unit cost estimates ($6.70 and $2.63 per client visit for the
societal and health care system, respectively, with a mean of 126
visits per client per year) were altered (±25%) in the sensitivity
analysis. We  ran sensitivity analysis including only costs from the
health care system perspective.
Cost-effectiveness  analysis
We  compared costs and effects of the intervention scenarios to
those of the current practice scenario. The incremental costs of the
intervention scenarios were divided by their incremental effects to
establish the incremental cost per HIV infection averted. We  dis-
counted both costs and effects at a 3% discount rate for both costs
and effects; this value was altered to 1% and 5% for effects and costs,
and to 0% for effects in our sensitivity analysis. The time horizon
of this study was 10 years, and was changed to 20 years in the
sensitivity analysis.
Results
The  HIV epidemic in West Java and the role of injecting drug use
Our  model simulations show a reasonably good ﬁt with the
observed prevalence of HIV among important risk groups (Fig. 1).
Our current practice scenario predicts that in West Java, without
any change in risk behaviours, the HIV prevalence in the overall
adult population will not reach 0.3% before 2020. HIV prevalence
among IDUs steadily approaches approximately 50% in the period
from 2010 until 2020. Although HIV prevalence among FSWs is
expected to grow considerably, the MSM  prevalence only grows
moderately (Fig. 1).
Intervention  impact and cost-effectiveness
Fig. 2 depicts the expected impact of different MMT  expansion
programs on HIV prevalence among IDUs. When MMT  is expanded
to a coverage level of 40% in 2019, the number of IDUs receiving
MMT will increase from approximately 500 in 2010 to approxi-
mately 4600 in 2019. The HIV prevalence among IDUs is expected
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Table  1
Parameter baseline values, sensitivity ranges and references used in adapted Asian Epidemic Model for West Java Province.
Parameter Baseline value Reference
AEM ﬁtting parameters
Transmission probability
Male  to female (Pm f) 0.00125 Fitting
Male to male (Pm m)  0.01790 Fitting
Needle stick 0.03 Fitting
Ratio of male to female versus female to male transmission 3.80 Fitting
IDU network parameter (%) 80 Fitting
STI cofactor
Female to male 16.00 Fitting
Male  to female 20.00  Fitting
Male to male 1.00 Fitting
Circumcision factor 2.55 Fitting
Epidemic start year
IDU 2002 Fitting
Heterosexual  1989 Fitting
MSM 1992 Fitting
Population sizes in West Java in 2006
FSW 0.32% NAC (2006)
FSW who  are direct FSWs (%) 62.20 NAC (2006)
IDU 0.08% NAC (2006)
MSM higher risk 0.13% NAC (2006)
MSM lower risk 1.1% NAC (2006)
MSW 0.02% NAC (2006)
Clients of FSWs 1.7% NAC (2006)
Males age 15+ 14,596,400 BPS  West Java
Females age 15+ 14,152,600 BPS West Java
HIV prevalence (% in 2007, used for ﬁtting)
Direct FSW (%) 10.35 IBBS 2007
Indirect FSW (%) 3.29 IBBS 2007
IDU 43.00 IBBS 2007
MSM 2.00 IBBS 2007
General population 0.00 IBBS  2007
Hetero sexual behavior and STIs
Direct female sex workers
Direct  to indirect FSW behavior movement each year (%) 1 Default value
Number of clients per day 1.7 IBBS 2007
Days worked per week 5.3 IBBS 2007
Condom use with clients (%) 62 IBBS 2007
Average duration of sex work (years) 2.5 IBBS 2007
STI prevalence (% Neisseria gonorrhea) 44 IBBS 2007
Indirect female sex workers
Number  of clients per day 0.86 IBBS 2007
Number of clients per day 5.5 IBBS 2007
Condom use with clients (%) 60 IBBS 2007
Average duration of sex work (years) 2.0 Local expert opiniona
STI prevalence (% Neisseria gonorrhea) 22 Local expert opinion
Clients of sex workers
Males  age 15–49 visiting sex workers (%) 1.7 NAC (2006)
Average duration of being a client (years) 11 Local expert opinion
Adult males circumcised (%) 87 DHS 2007
Male and female casual sex
Males having casual sex in last year (%) 0.3 Local expert opinion
Females having casual sex in last year (%) 0.1 Local expert opinion
Condom use in casual sex (%) 21 IBBS 2007
Average number of casual contacts in last year (male) 1 Default value
Sex with spouses or regular partners
Number of weekly sexual contacts with spouse/regular partner 1.4 Local expert opinion
Condom use with spouses or regular partners (%) 10 Local expert opinion
Adult population with STI (%) 0.5 Local expert opinion
IDU injecting and sexual behavior
IDU mortality (% additional mortality per year) 1.0 Default value
IDU sharing (%) 32 IBBS 2007, percentage
sharing  needle last
week
Injections shared, by those in sharing group (%) 70 IBBS 2007
Number of injections each day 0.74 IBBS 2007, the number
of  injections last week
divided  by 7.
Average duration of injecting (years) 8.0 IBBS 2007, a stable
population  is assumed.
As  12% of IDUs started
injecting  drugs less
than  one year ago, the
average  duration is
1/12%.
Sharing  to non-sharing movement in a year (%) 20 Local expert opinion
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Table 1 (Continued)
Parameter Baseline value Reference
Visiting FSWs (%) 41 IBBS 2007, percentage
visiting  sex workers
last  year
Condom use with direct FSW (%) 54 IBBS 2007, condom use
at  last commercial sex
Condom  use with indirect FSW (%) 54 IBBS 2007, condom use
at  last commercial sex
Condom  use with spouse or regular partner (%) 34 IBBS 2007, condom use
at  last sex
Number of contacts with regular partners (per week) 1 Default  value
Injecting sex workers (ISW)b
Injecting behaviors – higher frequency injecting SWs
Percent  of higher frequency sex workers who inject 0.1 IBBS 2007
Percent of higher frequency ISW in high risk networks 0 Default value
Percent of higher frequency ISW sharing 0 Default value
Percent of all injections shared (Sharing hi frequency SW) 0  Default value
Number of daily injections for higher frequency ISW 0.7  IBBS 2007
Average duration of injecting for higher freq ISW (years) 2.5 IBBS 2007
Percent condom use with clients (hi frequency ISWs) 62 IBBS  2007
Injecting behaviors – lower frequency injecting SWs
Percent of lower frequency sex workers who inject 0.1  IBBS 2007
Percent of lower frequency ISW in high risk networks 0 Default value
Percent of lower frequency ISW sharing 0 Default value
Percent of all injections shared (Sharing low frequency SW)  0 Default value
Number of daily injections for lower frequency ISW 0.7 IBBS 2007
Average duration of injecting for lower freq ISW (years) 2.5 IBBS  2007
Percent condom use with clients (low frequency ISWs) 60 IBBS 2007
MSM sexual behaviorc
Higher risk MSM  (Hi MSM)  sexual behavior
Reporting anal sex last year (%) 93 Local expert opinion
Number anal sex contacts last week 0.5 Local expert opinion
Average duration of same-sex behavior (years) 12.7 Local expert opinion
Shift from Hi MSM  to Lo MSM 25 Default value
MSM  having sex with other female partners (%) 34 Local expert opinion
Condom use in anal sex with other hi MSM  (%) 45  Local expert opinion
Prevalence hi MSM  with anal STI (%) 21 Local expert opinion
Lower risk MSM  (Lo MSM) sexual behavior
Percent of Lo MSM  reporting anal sex in last year 53 Local  expert opinion
Number anal sex contacts last week (for MSM  w/anal sex) 0.1 Local expert opinion
Average duration of same-sex behavior (years) 18.1 Local expert opinion
Percent of Lo MSM  with other female partners 20 Local expert opinion
Percent condom use in anal sex with other Lo MSM  48 Local expert opinion
Percent Lo MSM  with anal STI 5.4 Local expert opinion
MSM  sexual behavior with commercial partners
Percent of Hi MSM  visiting male sex workers 13 Local  expert opinion
Percent of Lo MSM  visiting male sex workers 2 Local expert opinion
Ratio of frequency of visiting MSW  (Lo MSM/Hi MSM) 0.1  Default value
Percent of Hi MSM  visiting female sex workers 6 Local expert opinion
Percent of Lo MSM  visiting female sex workers 0 Local expert opinion
Condom use in anal sex with male sex worker (%) 50 Local expert opinion
Condom use direct FSW (%) 62 IBBS 2007
Condom use indirect FSW (%) 60 IBBS 2007
Male sex workers (MSW)c
MSW  size and duration
Average  duration of male sex work (years) 6.3 Local expert opinion
Shifts from Hi MSM to MSW  1 Default value
Shifts from Lo MSM  to MSW  1 Default value
Sexual behaviors and STI with clients
Percent of MSW  reporting anal sex with clients in last year 93 Local expert opinion
Number anal sex contacts last week (for MSW  w/anal sex) 1.0 Local expert opinion
Percent MSW  with anal STI 23 Local expert opinion
Female partners of MSW
Percent  MSW  visiting female sex workers in last year 9 Local expert opinion
Percent MSW  with other female partners in last year 43 Local expert opinion
IDU = injecting drug users, FSW = female sex workers, MSM  = men  having sex with men, STI = sexual transmitted infections.
Note:  order and categorization of parameters are in line with presentation in Asian Epidemic Model.
a Local expert opinion was given by researchers from East West Center and AIDsina.
b The parameter values for Injecting sex workers are copied from both FSW and IDU parameter values.
c The IBBS 2007 report does not discriminate between MSM hi, MSM  lo and MSW,  but the raw IBBS data were used by local experts for parameter estimates.
to decrease to 40% in 2019. Compared with current practice, 2400
undiscounted HIV infections are expected to be averted by 2020, at
an undiscounted cost of US$16 million. Of these averted infections,
56% would be among IDUs, 24% among FSWs, 11% among clients,
9% among lower risk populations, and just one averted infection
would  be among MSM.  However, to put this into perspective, in
the same period there would still be 95,600 HIV infections in the
overall population. Expanding MMT  to 40% is expected to reduce
the number of infections among IDUs by 18%, while the effect on
FSWs, clients, and MSM  is expected to be negligible.
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Table  2
MMT  intervention impact matrix.a
Non-condom
use
Prevalence of
injecting  drug use
Frequency of
injection
Prevalence of
needle  sharing
Low −22% −46% −64% −30%
Average −32%  −47% −79% −63%
High  −42% −53% −88% −89%
a Source: Bollinger et al. (2007).
Table  3
Results of sensitivity analysis on cost-effectiveness of MMT.
Parameter ICERa current practice compared to no
intervention
Lower end Higher end
ICERb 6817
Time horizon is increased to 20 years 3767
Unit cost lower end = −25%, higher end = +25% 5113 8522
Unit  costs taken from health care system perspective 2676
Discount rate lower end = 1%, higher end = 5% 6661 6974
Discount  rate for effects = 0%, costs 3% 5638
IMPACT of interventionc, lower end: low impact, higher end: high impact. 8551 5313
IMPACT  of intervention – no effects on condom use 8654
IMPACT of intervention – no effect on condom use, neither on prevalence of injecting
drug use
11,813
CEAs on alternative scenarios
Alternative  1: PWID increased sexual risk behavior (all parameters +25% for risk
behavior, −25% for protective behavior).
5580
Alternative 2: PWID decreased sexual risk behavior (all parameters −25% for risk
behavior, +25% for protective behavior).
8521
Alternative 3: all injecting behaviors + 25% (except for additional mortality parameter). 6313
Alternative 4: all injecting behaviors − 25% (except for additional mortality parameter). 7027
Alternative 5: an enlarged (multiplied by 7) clients of sex workers population size and
smaller (divided by 1.15) FSW population size.d
6699
Alternative 6: increased (multiplied by 1.75) injection frequency.e,f 6775
Alternative 7: enlarged (multiplied by 3.14) IDU population size.e 7913
a ICER: incremental cost-effectiveness ratio: costs in US$ per infection averted.
b Assumptions in the CEA: time horizon is 10 years, an average impact of MMT  is assumed (Table 1), discount rate both for costs and effects is 3%, unit costs are 848.41$
per IDU on MMT  per year. Costs from 2010 until 2019 and effects from 2010 until 2019 were included.
c In Table 1 (methods), the different impacts are shown.
d To reduce the ‘Number of sex acts per IDU with FSWs per year’ and in this way  testing the link between IDU and FSW and the effect on CEA. Reductions and multiplications
follow alternative population size estimations.
e More dramatically than in alternative 3 and thereby testing the impact of this speciﬁc parameter on CEA.
f Using another indicator for injection frequency from IBBS 2007.
Table 3 shows that, in our baseline analysis, MMT  costs
approximately US$7000 per HIV infection averted. We  performed
extensive sensitivity analysis regarding the costs, epidemiologi-
cal input, and the cost-effectiveness analysis calculation itself, and
all incremental cost-effectiveness ratios (ICERs) fall within a fac-
tor two of US$7000 per HIV infection averted, with one exception.
When adopting the health care system perspective, the ICER equals
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Fig. 1. Reported and simulated HIV prevalence among high risk groups in West Java,
Indonesia. West Java projection for high risk groups (% older than 15 years, living
with  HIV) at current practice (5% coverage from 2010–2019) MMT.
US$2676 per infection averted. When neither effects on condom
use nor effects on the prevalence of injecting drug use were mod-
eled, the ICER increased to almost US$12,000 per infection averted.
Discussion
In this study, we analysed the cost-effectiveness of MMT  and
the role of injecting drug use in the West Javan HIV epidemic.
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Fig. 2. Predicted HIV/AIDS prevalence among IDUs in West Java, current practice
and intervention scenario.
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Our analysis suggests that MMT  costs approximately US$7000 per
HIV infection averted, and we found this value to vary within
a factor of two in the sensitivity analysis. The relevant question
here is whether MMT  in West Java is an economically attractive
intervention, and would merit further investment from the Indone-
sian government to make the services widely available. The World
Health Organisation, through its WHO-CHOICE program, deﬁnes
interventions that cost less than the gross domestic product (GDP)
per capita per disability-adjusted life year (DALY) averted as very
cost-effective, and those with a ratio that falls between one and
three times the GDP per capita as cost-effective (Torres, Baltussen,
Hutubessy, Acharya, & Evans, 2003). Assuming that one averted
HIV infection equates to approximately 26 averted DALYs (Tromp
& Baltussen, in press), MMT  would cost approximately US$269 per
DALY averted. Given that Indonesia’s GDP per capita is US$2858
(IMF, 2010), MMT  can be considered very cost-effective. A com-
parison with other interventions is more difﬁcult to make: MMT
compares favorably to other HIV-preventive interventions, such as
school-based education (Galarraga, Colchero, Wamai, & Bertozzi,
2009; Hogan, Baltussen, Hayashi, Lauer, & Salomon, 2005), but less
so to a multifaceted harm reduction program (including Needle and
Syringe Programs and others) in Bangladesh (Guinness et al., 2010).
These studies have been conducted in different contexts and are
therefore difﬁcult to compare. However, our study results conﬁrm
ﬁndings from Ukraine, where expanding MMT  was  also found to be
a cost-effective intervention (costing US$530 per quality-adjusted
life year gained) (Alistar, Owens, & Brandeau, 2011).
Our results show that expanding MMT  to 40% in 2019 will avert
approximately 2400 HIV infections by 2020. Strikingly, only 56%
of these infections will be prevented among IDUs. Two  factors are
of importance: the proportion of IDUs who share needles and the
impact of IDUs on the epidemic as a whole. These two factors are
discussed below in more detail.
In our one-way sensitivity analysis, we found ‘% of IDU shar-
ing’ to be the most important IDU-related parameter affecting the
cost-effectiveness estimates. This parameter, together with move-
ment in and out of this group, more or less determines the stable
equilibrium of HIV prevalence among IDUs. Because IDUs inject fre-
quently and HIV is transmitted very effectively via needles, almost
all IDUs who share needles become infected and the rapid spread
of HIV among IDUs is common (for an overview, see Saidel et al.,
2003). This also implies that when the epidemic has reached equi-
librium among IDUs, only those who start to share needles will
be likely to acquire new infections. New needle sharers comprise
a small proportion of a relatively stable cohort (in our study, the
average duration of being an IDU was 8 years), especially when
an intervention reduces the percentage of IDUs who share nee-
dles.
IDUs have played a signiﬁcant role in the West Javan HIV epi-
demic, and may  continue to do so in the future. The link between
IDUs and FSWs is strong: in our West Java projection, 41% of IDUs
reported visiting sex workers. Our West Java projection conﬁrms
the ﬁndings of Saidel et al. (2003) for a hypothetical population:
despite high-risk behaviour by FSWs and their clients, their HIV
prevalence remained low until the introduction of HIV among IDUs.
HIV initially spread rapidly among IDUs, and provided a boost to the
HIV epidemic among FSWs. Because of this strong link between
IDUs and FSWs, many infections among FSWs and their clients
would be averted when HIV incidence and prevalence among IDUs
is reduced by MMT.  Overall, our analysis suggests that the propor-
tion of incident cases caused by injecting drug use is expected to
decrease and to be replaced by infections caused by heterosexual
transmission. This is an important insight, and indicates the lim-
itations of interventions such as MMT:  although they may  offer
value for money and are therefore worthwhile, they are only able
to reduce incidence slightly (2.5% in our analysis).
Our analyses demonstrate a steady rise of HIV prevalence among
MSM, yet at a relatively low level. More profound analysis of the HIV
epidemic among MSM  is beyond the scope of this article. Although
our results appear soothing, given the MSM  epidemics in Asia,
HIV among MSM  certainly requires further investigation, including
cost-effectiveness analyses of interventions among MSM.
The  present analysis has a number of limitations. First, our
study was limited by the availability and quality of input parame-
ters, especially size of population groups and MMT  coverage rates.
Also, we  assumed that most behavioural parameters would remain
constant after 2007, and neglected trends such as the increased con-
sumption of methamphetamines, which may replace heroin use
and for which MMT  is not an effective treatment option. Yet our
extensive sensitivity analyses showed that study conclusions are
robust towards alternative assumptions on key variables, which
also supports the extrapolation of our ﬁndings to epidemics other
than the West Java epidemic.
Second, our analysis focused on MMT  and its impact on IDUs.
The evaluation of other interventions (such as the social marketing
of condoms among IDUs) was beyond the scope of our study, and
also impossible considering the absence of reliable cost informa-
tion. Nor did we  evaluate interventions targeting FSWs or MSM.
We acknowledge FSWs and MSM  as increasingly important risk
groups (as reﬂected in our simulations), and we  call for more
research on HIV among FSWs and MSM  in Indonesia, including
cost-effectiveness analyses of interventions that target these risk
groups.
Third, our estimates regarding the impact of MMT  were based
on international evidence, as summarised in the impact matrix of
the RNM (Bollinger et al., 2007), and may not necessarily reﬂect
reality in Indonesia. However, the assumed impact compares well
with evidence from pilot studies of MMT  at eight sites, including
Jakarta (Lawrinson et al., 2008). In Jakarta, opiate use dropped from
2.5 ± 1.4 to 0.43 ± 1.2 daily occasions of use after three months, and
to 0.51 ± 1.2 daily occasions of use after six months. Blood Borne
Virus Transmission Risk Assessment Questionnaire injecting risk
scores (which indicate unsafe injecting behaviour) dropped from
19.05 ± 17.9 to 5.23 ± 13.1 after three months and to 3.83 ± 9.3
after six months. Self-reported abstinence rates varied between
69 and 100% at six months. In addition, a recent international
systematic review (Gowing, Farrell, Bornemann, Sullivan, & Ali,
2011) of the impact of MMT  supports the RNM matrix. Because
of the absence of any Indonesian data to support reductions in
condom non-use and the prevalence of injecting drug use after
the implementation of MMT,  we ran a sensitivity analysis exclud-
ing these reductions and found that study conclusions did not
change.
Fourth, the present analysis considers the role of current IDUs in
HIV epidemics, but ignores the impact of recreational and former
IDUs. While MMT  is not indicated for these groups, they may  play
a role in the HIV epidemic in West Java; both populations may  be
important bridges to transfer HIV infections originating from inject-
ing drug use to the general population through sexual transmission.
In a recent survey from Indonesia, 44% of IDUs were classiﬁed as
former IDUs, of whom 66% were HIV-seropositive (Iskandar et al.,
2010).
Fifth, our analysis is somewhat limited in scope because we
did not consider antiretroviral treatment of IDUs. Treatment incurs
costs and reduces the transmission of HIV; however, because only
a small minority of all IDUs receives treatment, we do not expect
treatment outcomes to change our study conclusions. Furthermore,
our analysis did not value reductions in addiction-related crimes
and risk behaviours, regular contact of IDUs with medical services,
reestablishment of social and societal functioning, or collateral
health effects. These aspects are difﬁcult to measure and are seldom
included in cost-effectiveness analyses.
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Sixth, we present the cost-effectiveness of one intervention
only, and use international cost-effectiveness thresholds to classify
the interventions as very cost-effective. Ideally, all possible inter-
ventions to control HIV/AIDS in West Java should be ranked on the
basis of their cost-effectiveness, and investments should be geared
towards the most cost-effective interventions until the budget is
exhausted.
Seventh, our analysis shows that an expansion of MMT  is
warranted, but it does not tell us how the expansion should be
performed. IDUs are a stigmatised group, and harm reduction pro-
grams often lack political support or face legislative problems.
A lack of national capacity to expand harm reduction programs,
including issues of funding, has been observed throughout South-
east Asia (Sharma et al., 2009). Expanding MMT  to 40% would
require full commitment from the entire public health system (staff
commitment, infrastructure, materials) and political and legislative
support. Therefore, to successfully expand MMT,  careful consider-
ation and continuous attention to the political and organisational
challenges are needed.
In  sum, our analyses suggest that MMT  is a cost-effective HIV
prevention measure, and support government policies to make
MMT services widely available as an integrated component of
HIV/AIDS control in West Java.
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